CA2586553C - Nasal sprayer containing a formulation with olopatadine - Google Patents

Nasal sprayer containing a formulation with olopatadine Download PDF

Info

Publication number
CA2586553C
CA2586553C CA2586553A CA2586553A CA2586553C CA 2586553 C CA2586553 C CA 2586553C CA 2586553 A CA2586553 A CA 2586553A CA 2586553 A CA2586553 A CA 2586553A CA 2586553 C CA2586553 C CA 2586553C
Authority
CA
Canada
Prior art keywords
spray
olopatadine
formulation
sprayer
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2586553A
Other languages
English (en)
French (fr)
Other versions
CA2586553A1 (en
Inventor
Gerald Cagle
G. Michael Wall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of CA2586553A1 publication Critical patent/CA2586553A1/en
Application granted granted Critical
Publication of CA2586553C publication Critical patent/CA2586553C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/04—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air without heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2586553A 2004-11-24 2005-10-31 Nasal sprayer containing a formulation with olopatadine Expired - Lifetime CA2586553C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63088604P 2004-11-24 2004-11-24
US60/630,886 2004-11-24
PCT/US2005/039268 WO2006057769A2 (en) 2004-11-24 2005-10-31 Method of delivering nasal spray

Publications (2)

Publication Number Publication Date
CA2586553A1 CA2586553A1 (en) 2006-06-01
CA2586553C true CA2586553C (en) 2015-02-10

Family

ID=36498400

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2586553A Expired - Lifetime CA2586553C (en) 2004-11-24 2005-10-31 Nasal sprayer containing a formulation with olopatadine

Country Status (19)

Country Link
US (3) US20060110328A1 (enExample)
EP (1) EP1814538B1 (enExample)
JP (1) JP5068172B2 (enExample)
KR (1) KR101158603B1 (enExample)
CN (2) CN103860540A (enExample)
AT (1) ATE443516T1 (enExample)
AU (1) AU2005309951B2 (enExample)
BR (1) BRPI0518283A2 (enExample)
CA (1) CA2586553C (enExample)
CY (1) CY1110528T1 (enExample)
DE (1) DE602005016833D1 (enExample)
DK (1) DK1814538T3 (enExample)
ES (1) ES2331619T3 (enExample)
MX (1) MX2007005845A (enExample)
PL (1) PL1814538T3 (enExample)
PT (1) PT1814538E (enExample)
SI (1) SI1814538T1 (enExample)
WO (1) WO2006057769A2 (enExample)
ZA (1) ZA200704139B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6788460B2 (en) 1998-04-15 2004-09-07 Duke University Projection screen apparatus
US6829087B2 (en) 1998-04-15 2004-12-07 Bright View Technologies, Inc. Micro-lens array based light transmitting screen with tunable gain
US6816306B2 (en) 1998-04-15 2004-11-09 Bright View Technologies Inc. Micro-lens array based light transmitting screen with high resolution and low imaging artifacts
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
HUE026162T2 (en) 2007-02-07 2016-05-30 Novartis Ag Olopatadine preparation for topical nasal administration
PT2453872E (pt) * 2009-07-17 2013-10-30 Alcon Res Ltd Regime de pulverização nasal de olopatadina para crianças
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
GB2485604A (en) * 2010-11-22 2012-05-23 Martin Chard Device for marking a surface
US9937189B2 (en) * 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
ES2891729T3 (es) 2013-09-13 2022-01-31 Glenmark Specialty Sa Composición farmacéutica estable de dosis fija que comprende mometasona y olopatadina para la administración nasal
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
RU2686670C2 (ru) 2013-10-04 2019-04-30 Гленмарк Спешиалити С.А. Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN104063850B (zh) * 2014-06-24 2017-02-01 广东互维科技有限公司 红眼修复方法
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107569454B (zh) * 2017-09-29 2018-05-04 深圳大佛药业股份有限公司 一种盐酸奥洛他定鼻喷雾剂及其制备方法
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US11890409B1 (en) * 2019-11-19 2024-02-06 Saeed Rezakhany Methods of curing early stages of, and preventing, upper respiratory infections and applicators therefor
USD969992S1 (en) * 2020-12-23 2022-11-15 Aptar France Sas Device for nasal spray
CN119677523A (zh) * 2022-03-02 2025-03-21 V·杜加尔 一种用于保护和治疗粘膜的过氧化氢治疗喷雾剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (enExample) * 1956-03-21 1900-01-01
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
DE3882614T2 (de) * 1987-08-13 1993-11-18 Glaxo Group Ltd Indol-Derivate.
JPH0323237U (enExample) * 1989-07-19 1991-03-11
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
FR2803612B1 (fr) * 2000-01-12 2002-12-06 Michel Jean Louis Mar Doustaly Point d'eau sanitaire adaptable a une cuvette de wc
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
IT1317998B1 (it) * 2000-06-26 2003-07-21 Medical Internat Licensing N V Valvola erogatrice per spray nasale.
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US20040235955A1 (en) * 2001-09-14 2004-11-25 Masami Narita Remedies for pruritus
CN1297275C (zh) * 2002-11-12 2007-01-31 爱尔康公司 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol

Also Published As

Publication number Publication date
WO2006057769A2 (en) 2006-06-01
DE602005016833D1 (de) 2009-11-05
ES2331619T3 (es) 2010-01-11
AU2005309951A1 (en) 2006-06-01
CY1110528T1 (el) 2015-04-29
WO2006057769A3 (en) 2006-08-31
US20060110328A1 (en) 2006-05-25
EP1814538A2 (en) 2007-08-08
PT1814538E (pt) 2009-11-10
JP2008521488A (ja) 2008-06-26
SI1814538T1 (sl) 2010-01-29
JP5068172B2 (ja) 2012-11-07
EP1814538B1 (en) 2009-09-23
CA2586553A1 (en) 2006-06-01
KR101158603B1 (ko) 2012-07-09
EP1814538A4 (en) 2007-11-07
DK1814538T3 (da) 2009-11-02
KR20070086638A (ko) 2007-08-27
CN101065122A (zh) 2007-10-31
PL1814538T3 (pl) 2010-02-26
CN103860540A (zh) 2014-06-18
US20170172974A1 (en) 2017-06-22
BRPI0518283A2 (pt) 2008-11-11
MX2007005845A (es) 2007-07-04
AU2005309951B2 (en) 2011-07-07
US20140227326A1 (en) 2014-08-14
ATE443516T1 (de) 2009-10-15
ZA200704139B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
US20170172974A1 (en) Method of delivering nasal spray
AU739893B2 (en) A method for administration of active substances to the olfactory region
EP1933809B1 (en) Compositions for nasal delivery
SK12682003A3 (sk) Prípravky obsahujúce imidazotriazinón na nazálnu aplikáciu
CN115209884B (zh) 含有格隆溴铵和盐酸奥达特罗的可吸入制剂
EP1487409B1 (en) Highly aqueous liquid carrier formulations
WO2023133463A1 (en) Improved nasal administration of parkinson's therapeutics
CN118715013A (zh) 用于磷酸二酯酶抑制剂的鼻喷雾
CA3193390A1 (en) Nebulizer and nebulized anti-virals
CN108883079A (zh) 喷雾剂、喷雾装置以及喷雾组件
Varsha et al. An overview study on nasal and intranasal delivery system of drug
US20240423990A1 (en) Nasal Spray for Phosphodiesterase Inhibitors
WO2024228988A2 (en) Treatment for taste and smell loss
WO2024226493A2 (en) Treatment of memory loss with phosphodiesterase inhibitors
Pratapwar et al. Formulation and biological factors influencing the absorption of drugs through nasal epithelium and current nasal formulations-An overview

Legal Events

Date Code Title Description
EEER Examination request